NSE: DIVISLABHealthcareLarge Cap

Divi's Laboratories Ltd.

ISIN: INE361B01024 • Market Cap: ₹2.26 Lakh Cr

5-Pillar Score
73/100
Solid & Healthy
P/E Ratio77.37
ROCE19.4%
ROE15.3%
Debt to Equity0.00
3Y Sales CAGR12.7%
Promoter Holding51.9%
Detailed Quantitative Breakdown

The 5-Pillar Quality Audit for Divi's Laboratories Ltd.

Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:

1. Profitability & Capital Efficiency

Weight: 25%
81/ 100

Measures operating margins (35.3%), Return on Capital Employed (19.4%), and equity compounding (15.3%).

2. Financial Health & Solvency

Weight: 25%
82/ 100

Debt-to-Equity is 0.00 with comfortable interest coverage and clean working capital.

3. Growth & Compounding Track Record

Weight: 20%
79/ 100

Historical 3Y Sales CAGR (12.7%) and 3Y PAT CAGR (22.3%).

4. Valuation Multiple & Margin of Safety

Weight: 15%
25/ 100

Trades at P/E of 77.37 vs PEG of 4.99 and Dividend Yield of 0.3%.

5. Ownership Quality & Governance

Weight: 15%
85/ 100

Promoter holding stands at 51.9%, backed by 39.6% institutional ownership.

Key Fundamental Strengths

Fortress Balance Sheet (D/E: 0.00)

The company operates virtually debt-free, shielding net margins from interest rate cycles and monetary tightening.

High-Velocity Profit Compounding (3Y PAT CAGR: 22.3%)

Net earnings have compounded at 22.3% annualized, demonstrating operating leverage.

Deep Institutional Sponsorship (39.6%)

Mutual funds, domestic DIIs, and foreign FIIs hold 39.6%, providing strong governance scrutiny.

Areas to Watch & Potential Risks

Priced for Perfection (P/E: 77.37)

A steep valuation multiple of 77.37 leaves little margin for safety against quarterly earnings misses.

Sectoral & Macro Headwinds (Healthcare)

Subject to broader cyclical demand, raw material price shifts, and regulatory frameworks governing the Healthcare space.

Institutional Strategy Filters

Quantitative Strategy Eligibility

Checking DIVISLAB against established Indian wealth creation frameworks:

Eligible

Coffee Can Investing Framework

Passes Saurabh Mukherjea's Coffee Can rule: 10%+ sustained revenue growth and 15%+ ROCE/ROE.

Top Quartile

Quality Factor Screener (High RoIC + Low Debt)

Qualifies for Indian Quality Indices with overall score of 73/100 and clean gearing.

Watchlist

GARP / Value-Growth Blend

Valuation multiple or return metrics require further cyclical pullback.

Industry Benchmark

Healthcare Sector Peer Comparison

Compare DIVISLAB directly against top industry peers by market capitalization:

Company5-Pillar ScoreMarket CapP/EROCED/EScorecard
Divi's Laboratories Ltd. (DIVISLAB)Current73/100₹2.26 Lakh Cr77.3719.4%0.00—
Sun Pharmaceutical Industries Ltd. (SUNPHARMA)77/100₹4.55 Lakh Cr37.6520.4%0.05View
Torrent Pharmaceuticals Ltd. (TORNTPHARM)64/100₹1.91 Lakh Cr87.439.5%1.76View
Apollo Hospitals Enterprise Ltd. (APOLLOHOSP)70/100₹1.27 Lakh Cr60.5519.1%0.62View
Cipla Ltd. (CIPLA)63/100₹1.14 Lakh Cr33.9416.1%0.01View
Zydus Lifesciences Ltd. (ZYDUSLIFE)79/100₹1.10 Lakh Cr24.4221.9%0.43View

Frequently Asked Questions: Divi's Laboratories Ltd.

Q:What is the 5-Pillar Fundamental Score for Divi's Laboratories Ltd. (DIVISLAB)?

Divi's Laboratories Ltd. has a RupeeTools Fundamental Score of 73/100, placing it in the 'Solid & Healthy' category. Its pillar scores are: Profitability (81/100), Financial Health (82/100), Growth (79/100), Valuation (25/100), and Ownership Quality (85/100).

Q:Is DIVISLAB fundamentally strong for long-term investment?

Yes, DIVISLAB exhibits solid fundamental strength with a 73/100 score, driven by a return on equity of 15.3% and a debt-to-equity ratio of 0.00.

Q:Does DIVISLAB pass the Coffee Can Investing filter?

Yes! DIVISLAB satisfies both core pillars of Coffee Can Investing: achieving consistently high capital returns (ROCE/ROE >= 15%) alongside double-digit multi-year revenue growth.

Q:How does DIVISLAB compare against other Healthcare peers?

Within India's Healthcare sector, DIVISLAB trades at a P/E of 77.37 and generates an ROCE of 19.4%. Compare its 5-Pillar score of 73/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Torrent Pharmaceuticals Ltd. (64/100).

Regulatory & SEBI Research Analyst Compliance Disclaimer:

This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.